KR101096357B1 - 약물 서방성 입자 및 그 제법 - Google Patents

약물 서방성 입자 및 그 제법 Download PDF

Info

Publication number
KR101096357B1
KR101096357B1 KR1020057025130A KR20057025130A KR101096357B1 KR 101096357 B1 KR101096357 B1 KR 101096357B1 KR 1020057025130 A KR1020057025130 A KR 1020057025130A KR 20057025130 A KR20057025130 A KR 20057025130A KR 101096357 B1 KR101096357 B1 KR 101096357B1
Authority
KR
South Korea
Prior art keywords
particles
fatty acid
acid ester
melt
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057025130A
Other languages
English (en)
Korean (ko)
Other versions
KR20060026071A (ko
Inventor
유소 도모히라
Original Assignee
오쓰까 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오쓰까 세이야꾸 가부시키가이샤 filed Critical 오쓰까 세이야꾸 가부시키가이샤
Publication of KR20060026071A publication Critical patent/KR20060026071A/ko
Application granted granted Critical
Publication of KR101096357B1 publication Critical patent/KR101096357B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020057025130A 2003-06-27 2004-06-17 약물 서방성 입자 및 그 제법 Expired - Fee Related KR101096357B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2003-00184040 2003-06-27
JP2003184040 2003-06-27
PCT/JP2004/008824 WO2005000312A1 (ja) 2003-06-27 2004-06-17 薬物徐放性粒子及びその製法

Publications (2)

Publication Number Publication Date
KR20060026071A KR20060026071A (ko) 2006-03-22
KR101096357B1 true KR101096357B1 (ko) 2011-12-20

Family

ID=33549598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057025130A Expired - Fee Related KR101096357B1 (ko) 2003-06-27 2004-06-17 약물 서방성 입자 및 그 제법

Country Status (13)

Country Link
US (1) US8734843B2 (https=)
EP (1) EP1640006A4 (https=)
JP (1) JP4592590B2 (https=)
KR (1) KR101096357B1 (https=)
CN (2) CN1812793A (https=)
AR (1) AR045893A1 (https=)
AU (1) AU2004251541B2 (https=)
BR (1) BRPI0411882A (https=)
CA (1) CA2529475C (https=)
MX (1) MXPA05014194A (https=)
MY (1) MY145784A (https=)
TW (1) TW200505485A (https=)
WO (1) WO2005000312A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020063202A (ja) * 2018-10-16 2020-04-23 佐藤薬品工業株式会社 カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146553A1 (en) * 2002-12-23 2004-07-29 Aventis Pharma S.A. Compositions for oral administration of active principles requiring masking of taste
WO2006059716A1 (ja) * 2004-12-03 2006-06-08 Takeda Pharmaceutical Company Limited 固形製剤
ZA200805793B (en) * 2005-12-22 2009-11-25 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
CA2634059C (en) * 2005-12-22 2015-11-24 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
CA2681802C (en) * 2007-02-16 2015-12-08 Elevance Renewable Sciences, Inc. Wax compositions and methods of preparing wax compositions
US8142803B2 (en) 2007-03-22 2012-03-27 Magceutics, Inc. Magnesium compositions and uses thereof for neurological disorders
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
JP5870023B2 (ja) * 2010-02-22 2016-02-24 第一三共株式会社 経口用徐放性固形製剤
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
CN107050023A (zh) * 2017-01-13 2017-08-18 北京顺慈医药科技有限公司 一种盐酸小檗碱的制剂及遮盖药物不良味道的制剂方法
JP7293131B2 (ja) 2017-12-28 2023-06-19 住友ファーマ株式会社 新規微粒子コーティング（薬物含有中空粒子及びその製法）
CN111566130B (zh) 2018-01-05 2023-01-24 凸版印刷株式会社 复合颗粒、复合颗粒的制造方法、干燥粉体以及成型用树脂组合物
EP3786231A4 (en) 2018-04-27 2021-06-09 Toppan Printing Co., Ltd. DELAYED RELEASE COMPOSITE PARTICLES, METHOD FOR MANUFACTURING DELAYED RELEASE COMPOSITE PARTICLES, DRY POWDER AND WALLPAPER
CN108904451A (zh) * 2018-07-27 2018-11-30 广州柏赛罗药业有限公司 缓释制剂
US20210361581A1 (en) * 2018-10-22 2021-11-25 Ioi Oleo Gmbh Additive for a powder material intended for compaction into shaped bodies
CN114209887B (zh) * 2021-08-24 2023-03-03 杭州协合医疗用品有限公司 一种含可控降解聚酯微球的注射用凝胶
CN113877000B (zh) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 注射用微球组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003040764A (ja) * 2001-05-25 2003-02-13 Otsuka Pharmaceut Co Ltd 医薬用組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3264131A (en) * 1964-05-11 1966-08-02 Polymer Corp Process for fusion coating and materials used therein
JPH0647531B2 (ja) * 1986-02-06 1994-06-22 第一製薬株式会社 徐放性粒状物の製造法
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH03124063A (ja) * 1989-10-06 1991-05-27 Ricoh Co Ltd イメージセンサ
JP3078859B2 (ja) 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
IE65045B1 (en) * 1990-04-28 1995-10-04 Takeda Chemical Industries Ltd Granulated preparations and method of producing the same
JP2915590B2 (ja) 1991-02-15 1999-07-05 第一製薬株式会社 マスクされた粒状物
JP3130058B2 (ja) 1991-02-15 2001-01-31 第一製薬株式会社 マスクされた粒状物
US5359170A (en) 1992-02-18 1994-10-25 At&T Global Information Solutions Company Apparatus for bonding external leads of an integrated circuit
ES2194863T3 (es) 1992-11-30 2003-12-01 Kv Pharm Co Materiales farmaceuticos con enmascarado de sabor.
TW282403B (https=) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
KR100417746B1 (ko) 1995-07-21 2004-05-31 다이이찌 세이야꾸 가부시기가이샤 입상제제의제조방법
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
JP3372242B2 (ja) 1999-08-04 2003-01-27 沢井製薬株式会社 徐放性微粒子製剤及びその製造方法
JP2001055342A (ja) * 1999-08-17 2001-02-27 Sakamoto Yakuhin Kogyo Co Ltd 錠剤、錠菓用滑沢剤
AU781058B2 (en) * 1999-08-31 2005-05-05 Grunenthal Gmbh Delayed-action form of administration containing tramadol saccharinate
US6537671B2 (en) * 2000-12-05 2003-03-25 Alpha Coating Technologies, Llc Coating powders having enhanced electrostatic chargeability
JP2002179571A (ja) 2000-12-11 2002-06-26 Nikken Chem Co Ltd 小型徐放性錠剤
JP2002226304A (ja) 2001-01-31 2002-08-14 Mitsui Chemicals Inc 徐放型微粒子の製造方法
KR100913281B1 (ko) * 2002-02-21 2009-08-21 오츠카 세이야쿠 가부시키가이샤 서방 제제 및 그의 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003040764A (ja) * 2001-05-25 2003-02-13 Otsuka Pharmaceut Co Ltd 医薬用組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020063202A (ja) * 2018-10-16 2020-04-23 佐藤薬品工業株式会社 カフェインおよびヒヨスチアミン含有医薬組成物およびその製造方法

Also Published As

Publication number Publication date
HK1118484A1 (en) 2009-02-13
BRPI0411882A (pt) 2006-08-29
MY145784A (en) 2012-04-30
CA2529475A1 (en) 2005-01-06
AR045893A1 (es) 2005-11-16
CA2529475C (en) 2012-08-07
TW200505485A (en) 2005-02-16
AU2004251541B2 (en) 2010-03-04
MXPA05014194A (es) 2006-02-24
EP1640006A4 (en) 2012-04-04
US20070098843A1 (en) 2007-05-03
AU2004251541A1 (en) 2005-01-06
WO2005000312A1 (ja) 2005-01-06
JPWO2005000312A1 (ja) 2006-08-03
WO2005000312A8 (ja) 2005-02-24
KR20060026071A (ko) 2006-03-22
US8734843B2 (en) 2014-05-27
CN101219115A (zh) 2008-07-16
TWI333858B (https=) 2010-12-01
CN101219115B (zh) 2012-09-19
JP4592590B2 (ja) 2010-12-01
EP1640006A1 (en) 2006-03-29
CN1812793A (zh) 2006-08-02

Similar Documents

Publication Publication Date Title
KR101096357B1 (ko) 약물 서방성 입자 및 그 제법
FI119720B (fi) Pitkävaikutteisten rakeisten valmisteiden valmistusmenetelmä
KR100943347B1 (ko) 의약용 조성물
KR0168849B1 (ko) 피목 조성물 및 그의 제조방법
SI20677A (sl) Protiglivični peroralni preparat, ki vsebuje itrakonazol in postopek za njegovo pripravo
EP2153834A2 (en) Extended release pharmaceutical compositions comprising quetiapine salts
KR100913281B1 (ko) 서방 제제 및 그의 제조 방법
US20110311625A1 (en) Solid dosage forms of fenofibrate
JP2006518380A (ja) 固体分散体組成物
US20090304800A1 (en) Dry Coating using Twin-Screw Kneader
WO2007024123A1 (en) Pharmaceutical composition of pranlukast solid-dispersion with improved initial dissolution rate and the method of preparing the same
JP4779970B2 (ja) 経口製剤およびその製造方法
HK1118484B (en) Medicament sustained-release particles and method for preparing the same
JP4779192B2 (ja) 溶出制御された製剤用粒子
JP2004033820A (ja) 油溶性化合物含有乳化組成物の製造方法
JP2020152671A (ja) 水難溶性物質含有粒子
HK1065257B (en) Medicinal composition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20141120

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20151118

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20161214

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20161214

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000